C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study
In the EV-301 trial, enfortumab vedotin prolonged survival in patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy and programmed cell death 1/programmed death-ligand 1 inhibitor. However, real-world Asian data are limited, and potential pr...
Gespeichert in:
| Veröffentlicht in: | Cancers 2024-05, Vol.16 (9), p.1725 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 9 |
| container_start_page | 1725 |
| container_title | Cancers |
| container_volume | 16 |
| creator | Morikawa, Toshiharu Naiki, Taku Sugiyama, Yosuke Naiki-Ito, Aya Nagai, Takashi Etani, Toshiki Iida, Keitaro Isobe, Teruki Noda, Yusuke Shimizu, Nobuhiko Aoki, Maria Gonda, Masakazu Banno, Rika Kubota, Hiroki Ando, Ryosuke Umemoto, Yukihiro Kawai, Noriyasu Yasui, Takahiro |
| description | In the EV-301 trial, enfortumab vedotin prolonged survival in patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy and programmed cell death 1/programmed death-ligand 1 inhibitor. However, real-world Asian data are limited, and potential prognostic markers are non-existent. We aimed to investigate potential prognostic markers for enfortumab vedotin therapy in Asian patients.
We retrospectively enrolled 61 Japanese patients treated with enfortumab vedotin therapy at our hospital and affiliated hospitals between January 2019 and September 2023.
Enrolled patients (38 men, 23 women; median age 74 [IQR: 68-79] years) had bladder cancer (26 patients) or upper-tract urothelial carcinoma (35 patients). Fifty-four patients reported adverse events (grade >3 in 12). Skin disorders, pruritus, and neuropathy were common adverse effects. The median overall survival was 17.1 months (95% confidence interval: 10.0-not applicable). In multivariate analysis, the C-reactive protein level was an independent marker predicting favorable overall survival with enfortumab vedotin. Patient characteristics did not differ between C-reactive protein-high and -low groups.
Our study provides real-world data showing that enfortumab vedotin prolonged survival in Asian patients similar to the EV-301 trial. Additionally, the C-reactive protein level might be considered a prognostic marker of enfortumab vedotin therapy in such patients. |
| doi_str_mv | 10.3390/cancers16091725 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_3053978239</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A793567131</galeid><sourcerecordid>A793567131</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-35f4e73a3dfdf966f6ec637668e00930b613a52c48eca980e8a39b551775ea7e3</originalsourceid><addsrcrecordid>eNptkk1v1DAQhiMEolXpmRuyxIVLWjuzsWNuq6iFSl2xKi3XaNaZtC5JvNhOUX8XfxCnW74q7INH4-d9PWNNlr0W_AhA82ODoyEfhORaqKJ8lu0XXBW5lHrx_K94LzsM4ZanBSCUVC-zPagUcKnK_exHnV8QmmjviK29i2RHdhYYsnWKx2ixn9PXowvRGrZC_5U8S8wao0337LuNN2zZ3s2ltMx5tqKIIeJMXyW_G-pnjxq9saMbkF16wpjQB-HJ2DkfpwE37Au1LtrxPVuy1dRHm9fJPr11QdG7sKVdiZ_j1N6_yl502Ac6fDwPsqvTk8v6Y37-6cNZvTzPTeov5lB2C1KA0HZtp6XsJBkJSsqKONfAN1IAloVZVGRQV5wqBL0pS6FUSagIDrJ3O9-td98mCrEZbDDU9ziSm0IDvAStqgJ0Qt8-QW_d5MdU3QMlClCa_6GusafGpuajRzObNkuloZRKgEjU0X-otFsarHEjdTbl_xEc7wQm_VTw1DVbbwf0943gzTwpzZNJSYo3j-VOm4Ha3_yvuYCftCe7KQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3053123790</pqid></control><display><type>article</type><title>C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study</title><source>PubMed Central Open Access</source><source>MDPI - Multidisciplinary Digital Publishing Institute</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Morikawa, Toshiharu ; Naiki, Taku ; Sugiyama, Yosuke ; Naiki-Ito, Aya ; Nagai, Takashi ; Etani, Toshiki ; Iida, Keitaro ; Isobe, Teruki ; Noda, Yusuke ; Shimizu, Nobuhiko ; Aoki, Maria ; Gonda, Masakazu ; Banno, Rika ; Kubota, Hiroki ; Ando, Ryosuke ; Umemoto, Yukihiro ; Kawai, Noriyasu ; Yasui, Takahiro</creator><creatorcontrib>Morikawa, Toshiharu ; Naiki, Taku ; Sugiyama, Yosuke ; Naiki-Ito, Aya ; Nagai, Takashi ; Etani, Toshiki ; Iida, Keitaro ; Isobe, Teruki ; Noda, Yusuke ; Shimizu, Nobuhiko ; Aoki, Maria ; Gonda, Masakazu ; Banno, Rika ; Kubota, Hiroki ; Ando, Ryosuke ; Umemoto, Yukihiro ; Kawai, Noriyasu ; Yasui, Takahiro</creatorcontrib><description>In the EV-301 trial, enfortumab vedotin prolonged survival in patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy and programmed cell death 1/programmed death-ligand 1 inhibitor. However, real-world Asian data are limited, and potential prognostic markers are non-existent. We aimed to investigate potential prognostic markers for enfortumab vedotin therapy in Asian patients.
We retrospectively enrolled 61 Japanese patients treated with enfortumab vedotin therapy at our hospital and affiliated hospitals between January 2019 and September 2023.
Enrolled patients (38 men, 23 women; median age 74 [IQR: 68-79] years) had bladder cancer (26 patients) or upper-tract urothelial carcinoma (35 patients). Fifty-four patients reported adverse events (grade >3 in 12). Skin disorders, pruritus, and neuropathy were common adverse effects. The median overall survival was 17.1 months (95% confidence interval: 10.0-not applicable). In multivariate analysis, the C-reactive protein level was an independent marker predicting favorable overall survival with enfortumab vedotin. Patient characteristics did not differ between C-reactive protein-high and -low groups.
Our study provides real-world data showing that enfortumab vedotin prolonged survival in Asian patients similar to the EV-301 trial. Additionally, the C-reactive protein level might be considered a prognostic marker of enfortumab vedotin therapy in such patients.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers16091725</identifier><identifier>PMID: 38730675</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Adverse events ; Apoptosis ; Biomarkers ; Bladder cancer ; C-reactive protein ; Cancer ; Cancer patients ; Cancer therapies ; Carcinoma ; Care and treatment ; Cell death ; Chemotherapy ; Development and progression ; Gender ; Geriatrics ; Medical prognosis ; Medical research ; Medicine, Experimental ; Metastases ; Metastasis ; Multivariate analysis ; Neuropathy ; Neutrophils ; Nutritional status ; Patients ; Proteins ; Pruritus ; Skin diseases ; Tumors ; Urothelial carcinoma</subject><ispartof>Cancers, 2024-05, Vol.16 (9), p.1725</ispartof><rights>COPYRIGHT 2024 MDPI AG</rights><rights>2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c387t-35f4e73a3dfdf966f6ec637668e00930b613a52c48eca980e8a39b551775ea7e3</cites><orcidid>0000-0002-2257-3892 ; 0000-0002-7638-6048 ; 0000-0002-9635-4553 ; 0000-0001-7280-2481 ; 0009-0006-4430-0277 ; 0000-0001-8436-5872 ; 0000-0003-0828-2033 ; 0000-0003-2197-2477</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38730675$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morikawa, Toshiharu</creatorcontrib><creatorcontrib>Naiki, Taku</creatorcontrib><creatorcontrib>Sugiyama, Yosuke</creatorcontrib><creatorcontrib>Naiki-Ito, Aya</creatorcontrib><creatorcontrib>Nagai, Takashi</creatorcontrib><creatorcontrib>Etani, Toshiki</creatorcontrib><creatorcontrib>Iida, Keitaro</creatorcontrib><creatorcontrib>Isobe, Teruki</creatorcontrib><creatorcontrib>Noda, Yusuke</creatorcontrib><creatorcontrib>Shimizu, Nobuhiko</creatorcontrib><creatorcontrib>Aoki, Maria</creatorcontrib><creatorcontrib>Gonda, Masakazu</creatorcontrib><creatorcontrib>Banno, Rika</creatorcontrib><creatorcontrib>Kubota, Hiroki</creatorcontrib><creatorcontrib>Ando, Ryosuke</creatorcontrib><creatorcontrib>Umemoto, Yukihiro</creatorcontrib><creatorcontrib>Kawai, Noriyasu</creatorcontrib><creatorcontrib>Yasui, Takahiro</creatorcontrib><title>C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>In the EV-301 trial, enfortumab vedotin prolonged survival in patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy and programmed cell death 1/programmed death-ligand 1 inhibitor. However, real-world Asian data are limited, and potential prognostic markers are non-existent. We aimed to investigate potential prognostic markers for enfortumab vedotin therapy in Asian patients.
We retrospectively enrolled 61 Japanese patients treated with enfortumab vedotin therapy at our hospital and affiliated hospitals between January 2019 and September 2023.
Enrolled patients (38 men, 23 women; median age 74 [IQR: 68-79] years) had bladder cancer (26 patients) or upper-tract urothelial carcinoma (35 patients). Fifty-four patients reported adverse events (grade >3 in 12). Skin disorders, pruritus, and neuropathy were common adverse effects. The median overall survival was 17.1 months (95% confidence interval: 10.0-not applicable). In multivariate analysis, the C-reactive protein level was an independent marker predicting favorable overall survival with enfortumab vedotin. Patient characteristics did not differ between C-reactive protein-high and -low groups.
Our study provides real-world data showing that enfortumab vedotin prolonged survival in Asian patients similar to the EV-301 trial. Additionally, the C-reactive protein level might be considered a prognostic marker of enfortumab vedotin therapy in such patients.</description><subject>Adverse events</subject><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Bladder cancer</subject><subject>C-reactive protein</subject><subject>Cancer</subject><subject>Cancer patients</subject><subject>Cancer therapies</subject><subject>Carcinoma</subject><subject>Care and treatment</subject><subject>Cell death</subject><subject>Chemotherapy</subject><subject>Development and progression</subject><subject>Gender</subject><subject>Geriatrics</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Multivariate analysis</subject><subject>Neuropathy</subject><subject>Neutrophils</subject><subject>Nutritional status</subject><subject>Patients</subject><subject>Proteins</subject><subject>Pruritus</subject><subject>Skin diseases</subject><subject>Tumors</subject><subject>Urothelial carcinoma</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNptkk1v1DAQhiMEolXpmRuyxIVLWjuzsWNuq6iFSl2xKi3XaNaZtC5JvNhOUX8XfxCnW74q7INH4-d9PWNNlr0W_AhA82ODoyEfhORaqKJ8lu0XXBW5lHrx_K94LzsM4ZanBSCUVC-zPagUcKnK_exHnV8QmmjviK29i2RHdhYYsnWKx2ixn9PXowvRGrZC_5U8S8wao0337LuNN2zZ3s2ltMx5tqKIIeJMXyW_G-pnjxq9saMbkF16wpjQB-HJ2DkfpwE37Au1LtrxPVuy1dRHm9fJPr11QdG7sKVdiZ_j1N6_yl502Ac6fDwPsqvTk8v6Y37-6cNZvTzPTeov5lB2C1KA0HZtp6XsJBkJSsqKONfAN1IAloVZVGRQV5wqBL0pS6FUSagIDrJ3O9-td98mCrEZbDDU9ziSm0IDvAStqgJ0Qt8-QW_d5MdU3QMlClCa_6GusafGpuajRzObNkuloZRKgEjU0X-otFsarHEjdTbl_xEc7wQm_VTw1DVbbwf0943gzTwpzZNJSYo3j-VOm4Ha3_yvuYCftCe7KQ</recordid><startdate>20240501</startdate><enddate>20240501</enddate><creator>Morikawa, Toshiharu</creator><creator>Naiki, Taku</creator><creator>Sugiyama, Yosuke</creator><creator>Naiki-Ito, Aya</creator><creator>Nagai, Takashi</creator><creator>Etani, Toshiki</creator><creator>Iida, Keitaro</creator><creator>Isobe, Teruki</creator><creator>Noda, Yusuke</creator><creator>Shimizu, Nobuhiko</creator><creator>Aoki, Maria</creator><creator>Gonda, Masakazu</creator><creator>Banno, Rika</creator><creator>Kubota, Hiroki</creator><creator>Ando, Ryosuke</creator><creator>Umemoto, Yukihiro</creator><creator>Kawai, Noriyasu</creator><creator>Yasui, Takahiro</creator><general>MDPI AG</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-2257-3892</orcidid><orcidid>https://orcid.org/0000-0002-7638-6048</orcidid><orcidid>https://orcid.org/0000-0002-9635-4553</orcidid><orcidid>https://orcid.org/0000-0001-7280-2481</orcidid><orcidid>https://orcid.org/0009-0006-4430-0277</orcidid><orcidid>https://orcid.org/0000-0001-8436-5872</orcidid><orcidid>https://orcid.org/0000-0003-0828-2033</orcidid><orcidid>https://orcid.org/0000-0003-2197-2477</orcidid></search><sort><creationdate>20240501</creationdate><title>C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study</title><author>Morikawa, Toshiharu ; Naiki, Taku ; Sugiyama, Yosuke ; Naiki-Ito, Aya ; Nagai, Takashi ; Etani, Toshiki ; Iida, Keitaro ; Isobe, Teruki ; Noda, Yusuke ; Shimizu, Nobuhiko ; Aoki, Maria ; Gonda, Masakazu ; Banno, Rika ; Kubota, Hiroki ; Ando, Ryosuke ; Umemoto, Yukihiro ; Kawai, Noriyasu ; Yasui, Takahiro</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-35f4e73a3dfdf966f6ec637668e00930b613a52c48eca980e8a39b551775ea7e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adverse events</topic><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Bladder cancer</topic><topic>C-reactive protein</topic><topic>Cancer</topic><topic>Cancer patients</topic><topic>Cancer therapies</topic><topic>Carcinoma</topic><topic>Care and treatment</topic><topic>Cell death</topic><topic>Chemotherapy</topic><topic>Development and progression</topic><topic>Gender</topic><topic>Geriatrics</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Multivariate analysis</topic><topic>Neuropathy</topic><topic>Neutrophils</topic><topic>Nutritional status</topic><topic>Patients</topic><topic>Proteins</topic><topic>Pruritus</topic><topic>Skin diseases</topic><topic>Tumors</topic><topic>Urothelial carcinoma</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morikawa, Toshiharu</creatorcontrib><creatorcontrib>Naiki, Taku</creatorcontrib><creatorcontrib>Sugiyama, Yosuke</creatorcontrib><creatorcontrib>Naiki-Ito, Aya</creatorcontrib><creatorcontrib>Nagai, Takashi</creatorcontrib><creatorcontrib>Etani, Toshiki</creatorcontrib><creatorcontrib>Iida, Keitaro</creatorcontrib><creatorcontrib>Isobe, Teruki</creatorcontrib><creatorcontrib>Noda, Yusuke</creatorcontrib><creatorcontrib>Shimizu, Nobuhiko</creatorcontrib><creatorcontrib>Aoki, Maria</creatorcontrib><creatorcontrib>Gonda, Masakazu</creatorcontrib><creatorcontrib>Banno, Rika</creatorcontrib><creatorcontrib>Kubota, Hiroki</creatorcontrib><creatorcontrib>Ando, Ryosuke</creatorcontrib><creatorcontrib>Umemoto, Yukihiro</creatorcontrib><creatorcontrib>Kawai, Noriyasu</creatorcontrib><creatorcontrib>Yasui, Takahiro</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morikawa, Toshiharu</au><au>Naiki, Taku</au><au>Sugiyama, Yosuke</au><au>Naiki-Ito, Aya</au><au>Nagai, Takashi</au><au>Etani, Toshiki</au><au>Iida, Keitaro</au><au>Isobe, Teruki</au><au>Noda, Yusuke</au><au>Shimizu, Nobuhiko</au><au>Aoki, Maria</au><au>Gonda, Masakazu</au><au>Banno, Rika</au><au>Kubota, Hiroki</au><au>Ando, Ryosuke</au><au>Umemoto, Yukihiro</au><au>Kawai, Noriyasu</au><au>Yasui, Takahiro</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2024-05-01</date><risdate>2024</risdate><volume>16</volume><issue>9</issue><spage>1725</spage><pages>1725-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>In the EV-301 trial, enfortumab vedotin prolonged survival in patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy and programmed cell death 1/programmed death-ligand 1 inhibitor. However, real-world Asian data are limited, and potential prognostic markers are non-existent. We aimed to investigate potential prognostic markers for enfortumab vedotin therapy in Asian patients.
We retrospectively enrolled 61 Japanese patients treated with enfortumab vedotin therapy at our hospital and affiliated hospitals between January 2019 and September 2023.
Enrolled patients (38 men, 23 women; median age 74 [IQR: 68-79] years) had bladder cancer (26 patients) or upper-tract urothelial carcinoma (35 patients). Fifty-four patients reported adverse events (grade >3 in 12). Skin disorders, pruritus, and neuropathy were common adverse effects. The median overall survival was 17.1 months (95% confidence interval: 10.0-not applicable). In multivariate analysis, the C-reactive protein level was an independent marker predicting favorable overall survival with enfortumab vedotin. Patient characteristics did not differ between C-reactive protein-high and -low groups.
Our study provides real-world data showing that enfortumab vedotin prolonged survival in Asian patients similar to the EV-301 trial. Additionally, the C-reactive protein level might be considered a prognostic marker of enfortumab vedotin therapy in such patients.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>38730675</pmid><doi>10.3390/cancers16091725</doi><orcidid>https://orcid.org/0000-0002-2257-3892</orcidid><orcidid>https://orcid.org/0000-0002-7638-6048</orcidid><orcidid>https://orcid.org/0000-0002-9635-4553</orcidid><orcidid>https://orcid.org/0000-0001-7280-2481</orcidid><orcidid>https://orcid.org/0009-0006-4430-0277</orcidid><orcidid>https://orcid.org/0000-0001-8436-5872</orcidid><orcidid>https://orcid.org/0000-0003-0828-2033</orcidid><orcidid>https://orcid.org/0000-0003-2197-2477</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2024-05, Vol.16 (9), p.1725 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_3053978239 |
| source | PubMed Central Open Access; MDPI - Multidisciplinary Digital Publishing Institute; EZB-FREE-00999 freely available EZB journals; PubMed Central |
| subjects | Adverse events Apoptosis Biomarkers Bladder cancer C-reactive protein Cancer Cancer patients Cancer therapies Carcinoma Care and treatment Cell death Chemotherapy Development and progression Gender Geriatrics Medical prognosis Medical research Medicine, Experimental Metastases Metastasis Multivariate analysis Neuropathy Neutrophils Nutritional status Patients Proteins Pruritus Skin diseases Tumors Urothelial carcinoma |
| title | C-Reactive Protein Is a Potential Prognostic Marker in Patient with Advanced or Metastatic Urothelial Carcinoma Treated with Enfortumab Vedotin: A Multi-Center Retrospective Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A15%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=C-Reactive%20Protein%20Is%20a%20Potential%20Prognostic%20Marker%20in%20Patient%20with%20Advanced%20or%20Metastatic%20Urothelial%20Carcinoma%20Treated%20with%20Enfortumab%20Vedotin:%20A%20Multi-Center%20Retrospective%20Study&rft.jtitle=Cancers&rft.au=Morikawa,%20Toshiharu&rft.date=2024-05-01&rft.volume=16&rft.issue=9&rft.spage=1725&rft.pages=1725-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers16091725&rft_dat=%3Cgale_proqu%3EA793567131%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3053123790&rft_id=info:pmid/38730675&rft_galeid=A793567131&rfr_iscdi=true |